Doximity on the New York stock exchange for the first public offer on June 24, 2021.
Source: NYSE
Shares of Doximity On Thursday, 25% appeared in extended trade after the company had achieved results in the third quarter of 2025 in the third quarter of the analysts and output rosy guidelines.
This is how the company did:
- Win each share: 45 cents adapted compared to 34 cents that are expected by LSEG
- Revenue: $ 168.6 million compared to $ 152.8 million, which LSEG is expected
Doximity is a digital platform for medical specialists that helps clinicians to stay up to date in medical news, find paperwork, to find transfers and to carry out telemedical appointments with patients. The company mainly achieves income from its telemedicine tools, settings of solutions and marketing bans for customers such as pharmaceutical companies.
The sales of Doximity rose by 25%in the third quarter of $ 135.3 million in the same period of the previous year.
In his fourth quarter of the financial year, Doximity expects sales between 132.5 and 133.5 million USD to be expelled compared to estimates of the analysts of USD $ 123.8 million.
The company has also increased guidelines for its full financial year and expects it to report sales between 564.6 million and $ 565.6 million from the area of the company shared in the last quarter US dollars expected. Analysts expected 540 million US dollars for the year.
“We are proud to deliver another quarter of the record construction in quarter in the third quarter. Over 610,000 unique providers use our clinical workflow tools,” said Jeff Tangney, CEO from Doximity. “Our AI tools grown fastest in the last quarter and rose by 60% in the previous quarter, while our news feed exceeded more than a million unique providers.”
The company reported a net result of $ 75.2 million or 37 cents per share in the third quarter, compared to $ 48.0 million or 24 cents per share the previous year. The adjusted EBITDA from Doximity was USA 102.0 million, which rose by 39% of the previous year compared to the previous year.
Doximity was a ray of hope within the beaten digital health sector, which had exposed itself to a settlement because the companies had to adjust to a steamed growth environment. The company's share price more than doubled in 2024.
Comments are closed.